Literature DB >> 17546625

Synergistic induction of osteopontin by aldosterone and inflammatory cytokines in mesangial cells.

Stefan Gauer1, Ingeborg A Hauser, Nicholas Obermüller, Yvonne Holzmann, Helmut Geiger, Margarete Goppelt-Struebe.   

Abstract

Hypertensive nephrosclerosis is characterized by activation of the renin-angiotensin-aldosterone system in combination with an inflammatory response characterized by an infiltration of T-cells and mononuclear cells, which release proinflammatory cytokines like IL-1beta/TNFalpha. In various models of experimental hypertensive disease the chemokine osteopontin (OPN) enhances further leukocyte infiltration. Therefore, we investigated the induction of OPN expression in renal mesangial cells (MCs) by aldosterone and the inflammatory cytokines IL-1beta/TNFalpha. Incubation with aldosterone resulted in a time- and concentration-dependent increase in OPN mRNA and protein. OPN mRNA expression followed a biphasic time course with an early increase between 4 and 8 h and the second phase starting at 14 h. The early phase was independent of protein synthesis, indicating a direct effect of aldosterone. Aldosterone-mediated induction of OPN was prevented by spironolactone, indicative of a receptor-mediated aldosterone effect. The mineralocorticoid receptor (MR) was identified in MCs by RT-PCR and immunoprecipitation, and shown to interact with a putative aldosterone-response element of the OPN promoter. The proinflammatory cytokines IL-1beta and TNFalpha only marginally affected OPN expression in MCs. However, coincubation of aldosterone and the cytokines synergistically increased OPN mRNA and protein levels. Since the synergistic effect on OPN mRNA was inhibited by diphenyleneiodonium, we assume an involvement of reactive oxygen species (ROS). We conclude that the chemokine OPN is a target gene of aldosterone in renal MCs, which is activated via the MR, and that proinflammatory cytokines enhance aldosterone-dependent OPN expression. In vivo, this may result in further leukocyte infiltration aggravating hypertensive nephrosclerosis. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17546625     DOI: 10.1002/jcb.21433

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  9 in total

1.  In vivo osteopontin-induced macrophage accumulation is dependent on CD44 expression.

Authors:  Maria Cecilia G Marcondes; Matthew Poling; Debbie D Watry; DeShon Hall; Howard S Fox
Journal:  Cell Immunol       Date:  2008-08-03       Impact factor: 4.868

Review 2.  Oxidant Mechanisms in Renal Injury and Disease.

Authors:  Brian B Ratliff; Wasan Abdulmahdi; Rahul Pawar; Michael S Wolin
Journal:  Antioxid Redox Signal       Date:  2016-04-26       Impact factor: 8.401

3.  Aldosterone enhances IGF-I-mediated signaling and biological function in vascular smooth muscle cells.

Authors:  Teresa Cascella; Yashwanth Radhakrishnan; Laura A Maile; Walker H Busby; Katherine Gollahon; Annamaria Colao; David R Clemmons
Journal:  Endocrinology       Date:  2010-09-29       Impact factor: 4.736

4.  Glucose promotes the production of interleukine-1beta and cyclooxygenase-2 in mesangial cells via enhanced (Pro)renin receptor expression.

Authors:  Jiqian Huang; Helmy M Siragy
Journal:  Endocrinology       Date:  2009-10-27       Impact factor: 4.736

Review 5.  NOX enzymes and diabetic complications.

Authors:  Tomoko Kakehi; Chihiro Yabe-Nishimura
Journal:  Semin Immunopathol       Date:  2008-05-17       Impact factor: 9.623

6.  Hydrogen peroxide regulates osteopontin expression through activation of transcriptional and translational pathways.

Authors:  Alicia N Lyle; Ebony W Remus; Aaron E Fan; Bernard Lassègue; Grant A Walter; Arihiro Kiyosue; Kathy K Griendling; W Robert Taylor
Journal:  J Biol Chem       Date:  2013-11-18       Impact factor: 5.157

Review 7.  Osteopontin -- a promising biomarker for cancer therapy.

Authors:  Ran Wei; Janet Pik Ching Wong; Hang Fai Kwok
Journal:  J Cancer       Date:  2017-07-15       Impact factor: 4.207

8.  PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy.

Authors:  Stephen Orena; Tristan S Maurer; Li She; Rena Eudy; Vincent Bernardo; Darla Dash; Paula Loria; Mary E Banker; Meera Tugnait; Carlin V Okerberg; Jessie Qian; Carine M Boustany-Kari
Journal:  Front Pharmacol       Date:  2013-10-14       Impact factor: 5.810

Review 9.  Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone.

Authors:  N Muñoz-Durango; A Vecchiola; L M Gonzalez-Gomez; F Simon; C A Riedel; C E Fardella; A M Kalergis
Journal:  Biomed Res Int       Date:  2015-09-10       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.